Table 1.
Clinical and demographic characteristics of the sample and associations with SBI-R
| Associations with SBI-R | |||
|---|---|---|---|
| Total (n = 92) | |||
| M (SD) | r | p | |
| SBI-R | 8.3 (6.7) | - | - |
| Age (years) | 65.4 (9.2) | −0.03 | 0.75 |
| Body Mass Index | 26.1 (5.3) | 0.00 | 0.99 |
| Time since diagnosis (months) | 14.7 (14.3) | −0.13 | 0.23 |
| C-reactive protein (mg/L) | 1.37 (2.5) | 0.47 | <0.001 |
| Depression (PHQ-9 total score) | 6.0 (4.9) | 0.78 | <0.001 |
| SBI-R score | |||
| N (%) | M (SD) | P | |
| Disease type | 0.49 | ||
| Adenocarcinoma | 66 (71.0%) | 7.7 (6.5) | |
| Squamous cell CA | 7 (7.5%) | 9.3 (7.3) | |
| Small cell lung cancer | 14 (15.1%) | 10.6 (7.3) | |
| Not otherwise specified | 5 (5.4%) | NA | |
| Treatment type | 0.01 | ||
| Chemotherapy | 34 (40.5%) | 10.4 (7.5) | |
| Immunotherapy | 30 (35.7%) | 8.5 (6.4) | |
| Targeted therapy | 20 (23.8%) | 4.9 (3.8) | |
| Missing | 9 (9.7%) | NA | |
| Line of treatment | 0.80 | ||
| 1st | 49 (59.0%) | 8.1 (6.2) | |
| 2nd | 22 (26.5%) | 8.3 (7.1) | |
| 3rd or beyond | 12 (14.5%) | 9.6 (8.3) | |
| Missing | 10 (10.8%) | NA | |
| Gender | 0.65 | ||
| Female | 63 (67.7%) | 8.1 (6.2) | |
| Male | 29 (31.2%) | 8.8 (7.6) | |
| Race/Ethnicity | 0.02 | ||
| White | 79 (85.9%) | 7.5 (5.9) | |
| Non-white | 13 (14.1%) | 13.7 (8.5) | |
| Black | 7 (7.5%) | ||
| Hispanic | 5 (5.4%) | ||
| Asian | 1 (1.1%) | ||
| Married | 0.35 | ||
| Yes | 64 (69.5%) | 7.9 (6.1) | |
| No | 28 (30.4%) | 9.3 (7.8) | |
| Antidepressant | 0.36 | ||
| Yes | 20 (23.0%) | 9.6 (8.4) | |
| No | 73 (77.0%) | 8.0 (6.1) | |
PHQ-9, Patient Health Questionnaire; SBI-R, Sickness Behavior Inventory-Revised.